Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. The late-stage program in a high-need, specialized area of neuroscience expands Teva's innovative medicines pipeline, aligns with commercial strengths and supports both near- and long-term growth. Upon closing, Emalex shareholders to receive $700 million in cash with the possibility of up to an additional $200 million in commercial milestone payments, as well as net sales-based royalties, subject to regulatory approval PARSIPPANY, N.J. and CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Emalex Biosciences (“Emalex”) today announced a definitive agreement for Teva to acquire Emalex, including its lead asset, ecopipam. The positive Phase 3 data of ecopipam in children with Tourette syndrome demonstrated statistically significant results on the study's primary efficacy endpoint, and the NDA s
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Earnings Snapshot: Teva Pharmaceutical Industries tops Q1 estimates; maintains 2026 business outlook [Seeking Alpha]Seeking Alpha
- Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year-on-Year [Yahoo! Finance]Yahoo! Finance
- Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year-on-YearBusiness Wire
- Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined ExecutionGlobeNewswire
- Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth StrategyGlobeNewswire
TEVA
Earnings
- 4/29/26 - Beat
TEVA
Sec Filings
- 4/29/26 - Form 8-K
- 3/31/26 - Form DEFA14A
- 3/31/26 - Form ARS
- TEVA's page on the SEC website